<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overview of autoimmunity
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overview of autoimmunity
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overview of autoimmunity
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David S Pisetsky, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter H Schur, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            William FC Rigby, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Siobhan M Case, MD, MHS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 11, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autoimmune diseases are characterized by a pathologic response to self- or autoantigens; these responses can be categorized as autoimmunity or autoreactivity and underlie a wide range of clinical disorders. These disorders may be generalized, such as systemic rheumatic diseases like systemic lupus erythematosus, vasculitis, and others, or tissue- or organ-specific, such as endocrine and neurologic disorders, including autoimmune thyroiditis and multiple sclerosis, respectively, and other conditions. Autoimmune diseases can be either acute or chronic and can affect essentially all organs and body systems.
        </p>
        <p>
         An overview of autoimmunity is provided here, including discussions of the features common to and underlying autoimmune disorders and of steps for recognizing autoimmune disease. The clinical manifestations, diagnosis, and management of specific autoimmune conditions are described in detail separately. (See appropriate topic reviews.)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          DEFINITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autoimmune diseases are characterized by a pathologic state in which an aberrant immune response directed at a normal bodily constituent leads to inflammation, cell injury, or a functional disturbance with clinical manifestations [
         <a href="#rid1">
          1,2
         </a>
         ]. The molecular constituent (ie, protein, carbohydrate, nucleic acid) that is targeted in autoimmunity is called a "self"-antigen or an autoantigen; by contrast, a molecule from an infecting organism that stimulates an immune response is called a foreign antigen or "non-self." An autoimmune disease usually involves both a T and B cell response and can be generalized or tissue- or organ-specific and either acute or chronic.
        </p>
        <p>
         While autoimmune diseases are a pathologic state, autoimmunity nevertheless derives from the same mechanisms that underlie the normal immune response to foreign antigens. Immune responses can be divided into two broad categories: innate and adaptive. The innate immune response is a rapid and nonspecific response to a challenge, whether it arises from infection, trauma, or stress. By contrast, an adaptive immune response is slow (days to weeks) and involves the production of antigen-specific B or T cells to overcome a foreign challenge.
        </p>
        <p>
         While innate and adaptive immune responses (along with responsible cells and mediators) can be separated for analysis, an adaptive immune response depends upon the presence of an innate immune response to promote the generation of a specific immune response. Importantly, an adaptive immune response can be persistent and show memory. In this framework, an autoimmune disease results from a specific adaptive autoimmune response to an autoantigen; this response is in violation of the normal function of the immune system in which mechanisms of tolerance prevent "hyper-reactive" autoimmune responses to self-antigens.
        </p>
        <p>
         In general, treatment of an autoimmune disease requires agents to decrease the activity of the immune system (immunosuppressants) or block the inflammation (antiinflammatories) that lead to tissue injury. The definition of autoimmune disease does not specify the origin of the response nor its induction by a foreign or self-antigen. Depending upon evidence linking autoimmunity to a preceding infection, therapy in some conditions will be directed at a specific infection [
         <a href="#rid3">
          3,4
         </a>
         ]. In some instances, therapy relates to the functional disturbance (eg, insulin replacement therapy in type 1 diabetes).
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          STEPS FOR RECOGNIZING AUTOIMMUNE DISEASE
         </span>
        </p>
        <p class="headingAnchor" id="H1741986315">
         <span class="h2">
          Features of autoimmune disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of features characterize autoimmune disorders, and the determination that a disease is autoimmune involves various forms of clinical and laboratory evidence [
         <a href="#rid1">
          1,2
         </a>
         ]. The demonstration of autoantibodies is usually the first step in the diagnosis of an autoimmune disease, although it is not sufficient. The autoantibodies may not be the actual mediators of disease; naturally occurring autoantibodies can occur in immunologically competent people and may even rise nonspecifically during the course of disease or injury. Thus, some clinical manifestation should be evident in addition to the presence of autoantibody. Evidence for inherited susceptibility is often present in families of patients suspected of an autoimmune disease.
        </p>
        <p>
         Major characteristics include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Recognition of autoantibodies and target antigens
         </strong>
         – The usual first step is the demonstration of autoreactivity, which is most often an autoantibody to a tissue antigen. Even when associated with a clinical condition, autoantibodies may not mediate pathogenesis since naturally occurring autoantibodies can occur in immunologically competent people; levels of these antibodies may rise nonspecifically during the course of infection, cancer, or injury. These antibodies are usually of the immunoglobulin M (IgM) isotype and have low avidity for the self-antigen. Some natural autoantibodies may have beneficial or protective effects, accounting for their production during inflammatory conditions. Thus, the mere presence of a heightened level of autoantibodies does not by itself establish a cause-and-effect relationship.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although some autoimmune diseases affect a single or limited number of tissues, the target autoantigen may be widely expressed in the body and present in all cells. As such, the autoantigen may not have specific or even apparent relationship to the tissue affected or the clinical manifestations. By contrast, some autoantigens may be selectively expressed in a target tissue and have a clear relationship to pathophysiology (eg, receptor for a hormone or neurotransmitter). Such an antigen is called a tissue-specific antigen (TSA) or a tissue-restricted antigen (TRA). In addition, some autoantibodies to TSAs (eg, thyroid) may not be pathogenic. The differences between ubiquitously expressed molecules and TSAs are relevant for tolerance mechanisms. Finally, some inflammatory processes (eg, formation of neutrophil extracellular traps [NETosis]) appear able incite the production of certain autoantibodies (eg, anti-citrullinated protein antibodies [ACPA], proteinase 3, myeloperoxidase) that are strongly associated with clinical disease states such as rheumatoid arthritis or vasculitis [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A challenge in deciding whether a condition is autoimmune relates to the identification of the target antigen and the establishment of an immunoassay to detect the corresponding autoantibodies. In some instances, an assay can allow detection of a broad range of autoantibodies to cellular antigens and have utility as a general screen in patient evaluation. The antinuclear antibody (ANA) assay is the prime example of this kind of screening assay; ANA assays can detect antibodies to many different nuclear and cytoplasmic antigens [
         <a href="#rid6">
          6
         </a>
         ]. Assays of this kind can be informative in many different clinical settings, although, by their nature, these assays are not specific.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Another limitation of the ANA assay, in particular, relates to the detection of autoantibodies in the otherwise healthy population [
         <a href="#rid7">
          7
         </a>
         ]. The frequency of ANA positivity can approach 10 to 20 percent; this frequency may be increasing, suggesting some environmental influence leading to a general increase in autoreactivity [
         <a href="#rid8">
          8
         </a>
         ]. This situation provides further evidence that autoantibody production can occur in otherwise healthy individuals and that autoantibody production is not sufficient for clinical disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Because of advances in molecular biology, the identity of many self-antigens has been determined, and assays are now available for routine testing. These assays can help assess the role of autoimmunity in a particular condition and result from intensive searches for the presence of autoantibodies in conditions of previously unknown etiology. Such searches, for example, have demonstrated the presence of autoantibodies in paraneoplastic neurologic syndromes [
         <a href="#rid9">
          9
         </a>
         ]. Assays for autoantibodies can also allow the definition of new syndromes, as well as the subdivision of conditions into subtypes that may differ in clinical course and treatment response. Thus, discoveries of new autoantibodies in sera from patients with optic neuritis allow the definition of syndromes distinguished by reactivity to aquaporin 4 (AQP4) or myelin oligodendrocyte glycoprotein (MOG) [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For conditions characterized by a functional disturbance, an in vitro assay with cells from a tissue or a tissue culture line can be used to assess agonist or antagonist actions of a serum or purified antibody.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical autoimmunity
         </strong>
         – An autoimmune disease becomes clinically recognized at the time that the patient experiences disease manifestations in terms of signs and symptoms. This phase of disease can be called clinical autoimmunity. For some conditions, evidence of autoimmunity may predate clinical findings in terms of autoantibody production or abnormal immune reactivity such as increased cytokine production [
         <a href="#rid11">
          11,12
         </a>
         ]. Indeed, autoantibodies may be present many years before the diagnosis of a disease in the clinic such as systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid syndrome, and type 1 diabetes mellitus.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Pre-autoimmunity defines the period in which serologic and other immunologic findings are present but clinical manifestations are not yet apparent. Combined with genetic information or family history, the presence of elevated levels of autoantibodies may be highly predictive of the later onset of an autoimmune disorder and underpin efforts at prevention in individuals at high risk of disease [
         <a href="#rid13">
          13,14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inherited susceptibility
         </strong>
         – Genetic studies of families and of large populations of patients have demonstrated the role of inherited susceptibility factors in many autoimmune diseases. While genes of the major histocompatibility complex (MHC) are among the most prominent susceptibility factors, the genetics of disease in humans are complex, involving multiple genes whose array may differ among patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For some autoimmune diseases, over 100 genes have already been identified [
         <a href="#rid15">
          15
         </a>
         ]. These findings suggest that genetic factors may affect the poise or balance of the immune system, predisposing an affected individual to generating an autoimmune response to an antigenic challenge that would be without consequence in other individuals. While gene polymorphisms may influence the signaling thresholds of individual immune cells, several or more of such polymorphisms may be needed for a significant increase in autoreactivity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The use of genetic markers to predict disease depends on the frequency of the disease in a population, although targeted screening of family members who are a high risk (eg, siblings, identical twins) can be more productive.
        </p>
        <p>
        </p>
        <p>
         Formal demonstration that a disease is autoimmune in origin requires several kinds of evidence that have analogy to Koch postulates for showing that a disease arises from infection. For autoimmune disease, the term "Witebsky postulates" has sometimes been used to categorize the different types of evidence [
         <a href="#rid16">
          16,17
         </a>
         ]. (See
         <a class="local">
          'Direct evidence'
         </a>
         below and
         <a class="local">
          'Indirect evidence'
         </a>
         below and
         <a class="local">
          'Circumstantial evidence'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Direct evidence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Direct evidence of causality, a stringent level of evidence for autoimmunity, requires that an autoimmune response produces the characteristic pathologic features of the disease. This usually involves reproducing the disease totally or, in part, by transfer of autoantibody from a patient to a healthy recipient. This is typically demonstrated experimentally using transfer systems involving animals, although transfer of blood from a patient to an otherwise healthy subject has rarely occurred, and in vitro or model test systems have also been used. An important void in studies of human autoimmune disease is the lack of methods that directly show the pathogenic effects of T cells by adoptive transfer.
        </p>
        <p>
         Examples of direct evidence include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antibody transfer from human patient to animal model
         </strong>
         – One striking example of antibody transfer was the reproduction of pemphigus by injection of patient serum into a neonatal mouse [
         <a href="#rid18">
          18
         </a>
         ]. This procedure reproduced the essential pathologic features of the disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transplacental human-to-human autoantibody transfer
         </strong>
         – Human-to-human transfer of autoantibody may result from transplacental transmission of the disease. Examples of maternal-fetal transmission have been well documented in cases of Graves' disease [
         <a href="#rid19">
          19
         </a>
         ], myasthenia gravis [
         <a href="#rid20">
          20
         </a>
         ], and the complete heart block and other cardiac abnormalities in neonatal lupus associated with maternal lupus and Sjögren's disease [
         <a href="#rid21">
          21
         </a>
         ]. Most of the clinical manifestations in the offspring are temporary because the autoantibody in these cases is provided through passive transfer of serum from the mother. An exception is the congenital heart block and other cardiac abnormalities of neonatal lupus, which are persistent and potentially life threatening. In this situation, the heart block may be the outcome of intense local inflammation damaging cells of the conduction system [
         <a href="#rid22">
          22,23
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5620.html" rel="external">
          "Pathogenesis of Sjögren’s disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4679.html" rel="external">
          "Pregnancy in women with systemic lupus erythematosus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6402.html" rel="external">
          "Neonatal lupus: Epidemiology, pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Autoantibody effects in vitro
         </strong>
         – There are situations in which the pathologic effects of antibody can be reproduced in an in vitro model system. Examples are found in diseases of the blood, such as hemolytic anemia, leukopenia, or thrombocytopenia (see
         <a class="medical medical_review" href="/z/d/html/7084.html" rel="external">
          "Cold agglutinin disease", section on 'Pathogenesis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7078.html" rel="external">
          "Warm autoimmune hemolytic anemia (AIHA) in adults", section on 'Direct antiglobulin (Coombs) testing'
         </a>
         ). Antiphospholipid antibodies, another example, are autoantibodies that may affect blood clotting in laboratory tests [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4678.html" rel="external">
          "Diagnosis of antiphospholipid syndrome", section on 'Patients on an anticoagulant'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         An important gap in studying autoimmunity relates to methods to show the pathogenic effects of T cells. Efforts have been made to adapt immunodeficient animals as "living test tubes" for the demonstration of autoimmune-induced pathology. Experiments designed to show the effects of cytotoxic lymphocytes against human tissue cells in the test tube require that the cells be cultured in vitro while retaining their native antigens.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Indirect evidence
         </span>
         <span class="headingEndMark">
          —
         </span>
         A second type of evidence to show causality comes from the simulation of disease in an experimental animal. Different animal models are utilized for this purpose: reproduction of disease in animals via immunization with the appropriate self-antigen, naturally occurring disease in animals that resembles its human counterpart, and disease resulting from manipulation of the immune system. (See
         <a class="local">
          'Immunization with self-antigen'
         </a>
         below and
         <a class="local">
          'Naturally occurring disease in animals'
         </a>
         below and
         <a class="local">
          'Immune system manipulation'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1025915499">
         <span class="h3">
          Immunization with self-antigen
         </span>
         <span class="headingEndMark">
          —
         </span>
         Two examples illustrate the use of immunization with self-antigen to mimic human autoimmune disorders:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Autoimmune thyroiditis
         </strong>
         – A good example of an experimental model is autoimmune thyroiditis in the mouse [
         <a href="#rid25">
          25
         </a>
         ]. Here, the experimental antigen, thyroglobulin, is a major target of autoantibody production in patients. In genetically susceptible strains of mice, immunization with thyroglobulin produces a pathologic picture of chronic thyroiditis that closely resembles the human disease (see
         <a class="medical medical_review" href="/z/d/html/7854.html" rel="external">
          "Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)"
         </a>
         ). Another useful example is myocarditis, which can be reproduced by immunization of susceptible mice with murine myosin [
         <a href="#rid26">
          26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4933.html" rel="external">
          "Myocarditis: Causes and pathogenesis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Experimental autoimmune encephalomyelitis
         </strong>
         – One of the most widely studied models of autoimmune disease induced by immunization is experimental autoimmune encephalomyelitis (EAE) [
         <a href="#rid27">
          27,28
         </a>
         ]. The demyelinating changes in the experimental disease show similarities to multiple sclerosis in humans. Three antigens can induce this disease in rodents: myelin basic protein (MBP), proteolipid protein (PLP), and myelin oligodendrocyte glycoprotein (MOG). Immunization with MOG produces axonal loss as well as demyelination and has a relapsing and remitting course similar to multiple sclerosis in humans [
         <a href="#rid29">
          29
         </a>
         ]. Manipulation of components of the immune system, such as the introduction of a T cell receptor for a disease-producing antigen into an otherwise disease-resistant strain, can further define steps in the autoimmune process [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Naturally occurring disease in animals
         </span>
         <span class="headingEndMark">
          —
         </span>
         Another type of disease model is derived from naturally occurring disease in animals that resembles its human counterpart. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mouse models of systemic lupus erythematosus
         </strong>
         – Diseases with features of systemic lupus erythematosus occur in particular inbred strains of mice. These strains include the NZB/NZW F1 hybrid, MRL/lpr, and BXSB [
         <a href="#rid31">
          31
         </a>
         ]. These mice express autoantibodies to deoxyribonucleic acid (DNA; anti-DNA), a characteristic antibody of systemic lupus erythematosus, along with renal disease that is mediated by immune complexes. Cell-transfer experiments clearly establish these diseases as autoimmune in origin [
         <a href="#rid32">
          32,33
         </a>
         ]. Development of autoimmunity in these mice is spontaneous and does not require any immunization, although environmental factors may affect the course of disease. Among these factors, the microbiome may have an important role in determining the development of disease [
         <a href="#rid34">
          34
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4669.html" rel="external">
          "Epidemiology and pathogenesis of systemic lupus erythematosus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonobese diabetic mouse model of type 1 (autoimmune) diabetes
         </strong>
         – Another important spontaneous model is the nonobese diabetic (NOD) mouse, which develops a disease closely resembling type 1 (autoimmune) diabetes [
         <a href="#rid35">
          35
         </a>
         ]. These mice have been particularly useful for delineating the major genetic traits that increase susceptibility to the disease, some of which also appear to operate in human type 1 diabetes and other autoimmune diseases [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Whether induced or spontaneously occurring, animal models are also important for testing interventions including pharmacologic agents that may reveal mechanisms or provide proof-of-principle data for preclinical drug development. While these animal model systems resemble features of human disease, there are nevertheless important differences in underlying mechanisms that lead to caution in extrapolating information to the human situation.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Immune system manipulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies with genetically manipulated mice indicate that a wide range of genes involving the immune system can contribute to autoimmunity [
         <a href="#rid37">
          37,38
         </a>
         ]. These studies employ molecular biologic techniques that enable the creation of mice in which a particular gene can have increased expression (eg, transgenic mice) or decreased expression (eg, gene deletion or "knockout" mice). With a change in expression of a single gene, disease with features of systemic lupus erythematosus, for example, can occur, but the occurrence of disease can differ among inbred strains, pointing to epistatic effects, by which the phenotypic effect of the change depends upon variants in one or more other genes.
        </p>
        <p>
         The most important genetic trait in determining susceptibility to autoimmune disease is the human class II MHC human leukocyte antigen (HLA). Replacing the MHC of a mouse with a human susceptibility HLA haplotype can render the mouse susceptible to spontaneous autoimmune disease [
         <a href="#rid39">
          39
         </a>
         ]. For instance, simply inserting the susceptible HLA haplotype can induce spontaneous myocarditis in previously resistant mice [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
         As a further example of a genetic immune manipulation that results in autoimmune disease, models of inflammatory bowel disease have been described in animals in which particular cytokines such as interleukin (IL) 2 and IL-10 have been eliminated [
         <a href="#rid41">
          41,42
         </a>
         ]. Another example is in mice deficient in programmed cell death (PD) 1 immunoinhibitory coreceptor that develop autoimmune dilated cardiomyopathy with production of high titers of autoantibodies against cardiac troponin-1 [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         It has become possible to relate these findings on immune system manipulation in animal experiments to human subjects receiving immune checkpoint blockade as cancer immunotherapy. Some of the patients develop autoimmune disease that resembles the spontaneous condition [
         <a href="#rid44">
          44,45
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">
          "Toxicities associated with immune checkpoint inhibitors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/114506.html" rel="external">
          "Rheumatologic complications of checkpoint inhibitor immunotherapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Circumstantial evidence
         </span>
         <span class="headingEndMark">
          —
         </span>
         The lowest level of proof, circumstantial evidence, is the one most commonly available to attribute an enigmatic human disease to autoimmunity. Such evidence may include systemic inflammation, the presence of autoantibodies, clustering of diseases within an individual or family, bias to certain HLA haplotypes, a sex bias, and a response to immunosuppressive therapy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Systemic inflammation and autoantibodies
         </strong>
         – Circumstantial evidence can suggest that an enigmatic human disease results from autoimmunity. The first piece of suggestive evidence is frequently evidence of systemic inflammation (eg, increased sedimentation rate, increased levels of C-reactive protein), along with findings of immune activation such as increased levels of immunoglobulins. The presence of autoantibodies also suggests an autoimmune process. While there are now assays for a very large number of autoantibodies, initial screening may involve testing for ANAs. The limitation of using this kind of evidence for positing a disease as autoimmune is the high frequency of false-positive results. Natural autoantibodies are very common and may rise nonspecifically during a disease process [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Familial clustering and genetic factors
         </strong>
         – A second kind of circumstantial evidence comes from the finding that autoimmune diseases tend to cluster, probably because they share some genetic susceptibility traits. As examples, a single individual may have more than one autoimmune disease, and members of the family share the same or other, related autoimmune diseases. The association of one disease of unclear etiology with another of authentic autoimmune etiology strengthens the possibility that the former is also an autoimmune disorder [
         <a href="#rid47">
          47,48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As stated above, the best-studied autoimmune diseases show a particular bias to certain HLA haplotypes, usually the class II category. Since the class II MHC genes are critical in antigen presentation and disease induction, they can modulate the autoimmune response [
         <a href="#rid49">
          49
         </a>
         ]. Next, a large number of regulatory genes contribute to normal immunologic homeostasis. Allelic differences in these genes
         <strong>
         </strong>
         may contribute to a greater or lesser susceptibility to various autoimmune diseases. These genes include such regulatory genes as
         <em>
          CTLA4
         </em>
         and
         <em>
          PTPN22
         </em>
         [
         <a href="#rid50">
          50,51
         </a>
         ]. Yet, in the aggregate, all of these heritable traits, including polymorphisms of MHC class II and regulatory genes, contribute less than half of the susceptibility to autoimmune diseases, even in genetically identical twins [
         <a href="#rid52">
          52
         </a>
         ]. As an example, a retrospective cohort study from Sweden found that monozygotic identical twin concordance for ACPA with or without rheumatoid arthritis was less than 5 percent [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition, postgenomic epigenetic effects add to incomplete concordance of monozygotic twins. Epigenetic changes in gene expression occur by mechanisms other than alterations in the DNA sequence. These changes include methylation of DNA nucleotides and histone post-translational modifications affecting chromatin structure. These and many other epigenetic changes account for the fact that even monozygotic twins do not have identical immune responses [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Thus, the majority of patients with an autoimmune disease present without a clear family history. In part, this paradox underlines the key role of environmental factors as triggers of autoimmune disease in genetically more susceptible individuals. (See
         <a class="local">
          'Inductive mechanisms'
         </a>
         below and
         <a class="local">
          'Pathogenetic mechanisms'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sex bias
         </strong>
         – Most, but not all, autoimmune diseases are more common in women than men. A sex bias, therefore, provides increased circumstantial evidence of an autoimmune etiology. The sex-based differences in autoimmune diseases have provided new information on the important role of
         <strong>
         </strong>
         sex hormones in the pathogenesis of autoimmune disease [
         <a href="#rid48">
          48,55,56
         </a>
         ]. Genes on the X-chromosome involved with immunoregulation can also contribute to susceptibility to autoimmunity, especially if these genes are overexpressed because of disturbances of X-chromosome inactivation, the mechanism by which one X-chromosome is inactivated in each cell [
         <a href="#rid57">
          57,58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Response to immunosuppressive therapy
         </strong>
         – Finally, the favorable response of a disease to immunosuppressive treatment is often an initial clinical hint of a possible autoimmune etiology. Of these treatments, glucocorticoids have both antiinflammatory and immunosuppressive actions that can reduce symptoms of many diseases, including infections, suggesting caution in inferring autoimmunity from a pharmacologic effect.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          INDUCTIVE MECHANISMS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of B and/or T cell autoreactivity is the defining characteristic of an autoimmune disease. While B and/or T cell autoreactivity may be the proximate cause of disease, an autoimmune response results from the complex interplay of multiple cell populations including antigen-presenting cells, T helper (Th) cells, B cells, and regulatory cells, among others, with cytokines influencing the magnitude of these responses at multiple levels.
        </p>
        <p>
         An autoimmune response can be initiated by an autologous (self) or foreign (non-self) antigen; induction by a foreign antigen suggests structural similarity with an autoantigen, with this cross-reactivity denoted as molecular mimicry. Identification of a molecular mimic can involve a search for shared amino acid sequences between a foreign and self-antigen. Thus, the binding of antibodies to both a foreign and self-antigen provides further evidence for molecular mimicry. Studies of this kind have provided evidence for molecular mimicry in diseases such as rheumatoid arthritis [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
         Like all immune responses, autoimmunity appears under genetic control of antigen recognition, cellular interactions, and eventual outcomes. In addition, environmental agents may promote autoimmune responses [
         <a href="#rid60">
          60
         </a>
         ]. Infections, for example, can provide the requisite antigen by mimicking or altering of self-antigens or heightening the overall level of immune reactivity or by causing antigen "spillage" [
         <a href="#rid61">
          61,62
         </a>
         ].
        </p>
        <p>
         Even without an infection, microorganisms may also influence both the initiation and progression of an autoimmune response. In individuals, populations of commensal microorganisms ("microbiota") can profoundly affect the induction of such diseases as inflammatory bowel diseases [
         <a href="#rid63">
          63
         </a>
         ]. The gut or gastrointestinal tract is the largest source of microorganisms in the body including bacteria, viruses, and fungi, but microorganisms also inhabit the skin and mucus membranes. Changes in the composition of the microbiota can occur in autoimmune disease producing a state known as dysbiosis [
         <a href="#rid64">
          64,65
         </a>
         ]. As an example, the increased levels of a specific gut organism
         <em>
          (Ruminococcus gnavus
         </em>
         ) are associated with lupus nephritis in humans [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
         Organisms in the microbiome may also enter the blood because of impaired gut permeability and directly contact cells of the immune system. Thus, studies indicate that
         <em>
          Enterococcus gallinarum
         </em>
         can be found in the liver of patients with systemic lupus erythematosus, with cross-reactivity contributing an autoimmune response to the Ro antigen [
         <a href="#rid67">
          67
         </a>
         ]. In addition, infection can provide the inflammatory context that favors immune responses, through activation of the innate immune responses [
         <a href="#rid68">
          68
         </a>
         ]. Thus, attention has focused on the Epstein-Barr virus as an instigating agent in different autoimmune diseases, multiple sclerosis, and systemic lupus erythematosus [
         <a href="#rid69">
          69,70
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          PATHOGENETIC MECHANISMS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The development of autoimmune disease depends upon an imbalance between pathogenic factors generated by autoreactive T and B cells and the regulatory factors that normally control the immune response. Despite their diverse etiologies, autoimmune diseases display certain pathogenetic mechanisms in common. With few exceptions, development of these diseases requires the presence of self-reactive CD4-positive T lymphocytes to promote antigen-specific responses. Diseases in which there is a chronic inflammatory response but no evidence of adaptive immunity in the form of self-reactive T cells may reflect increased activation of innate immunity and can represent autoinflammatory diseases [
         <a href="#rid71">
          71
         </a>
         ]. (See
         <a class="local">
          'Autoinflammatory diseases'
         </a>
         below.)
        </p>
        <p>
         The following regulatory and pathogenic factors contribute to the pathogenesis of autoimmune disease:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Breakdown or defects in immune tolerance
         </strong>
         – Autoimmune disease represents a breakdown in the normal mechanisms that prevent autoreactivity of both T and B cells. These mechanisms affect the development and regulation of multiple cell populations and act both centrally as well as peripherally. For T cells, the thymus is the locale for the establishment of central tolerance, while the bone marrow is the locale for B cells. Central tolerance may not be complete, however, and autoreactive cells can emerge in the periphery following somatic mutation, especially among B cells. Thus, in addition to deletion and elimination of cells in the thymus or bone marrow, other regulatory interactions are necessary to restrain autoreactivity [
         <a href="#rid72">
          72-74
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Thymic selection is critical for normal T cell development and is dependent upon interaction with antigen-presenting cells in the thymus for steps called positive and negative selection. The interactions and the cells responsible for antigen presentation differ for ubiquitously expressed antigens and those that are tissue selective or restricted. The autoimmune regulator (
         <em>
          AIRE
         </em>
         ) gene is an autosomal recessive gene that is responsible for intrathymic presentation of autologous antigen tissue-restricted antigens (TRAs) whose expression would otherwise be insufficient to allow the establishment of tolerance. Mutations in the
         <em>
          AIRE
         </em>
         gene cause several combinations of autoimmune endocrine diseases, such as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), because the appropriate self-antigens are not properly presented in the thymus [
         <a href="#rid75">
          75
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13569.html" rel="external">
          "Chronic mucocutaneous candidiasis", section on 'Clinical features of AIRE deficiency/APECED'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although there is experimental evidence that deletion of self-reactive lymphocytes occurs in the thymus, this mechanism seems to mostly affect prominent systemically expressed antigens, such as those of the major blood groups and histocompatibility complex [
         <a href="#rid76">
          76
         </a>
         ]. By comparison, in the case of most other self-antigens, deletion of self-reactive T cells in the thymus is lacking or incomplete. Fortunately, mechanisms in the periphery can retard the activation of self-reactive T cells that escape deletion in the thymus.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Another mechanism of peripheral self-tolerance involves immunologic ignorance, that is, the lack of a productive encounter between the T cell and its corresponding peptide/major histocompatibility complex (MHC) complex on an antigen-presenting cell. Ignorance can be overcome by changes in antigen availability, such as presentation by an infecting microorganism [
         <a href="#rid77">
          77
         </a>
         ]. These events can cause autoimmunity and possibly give rise to autoimmune disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Defects in active regulation and control of autoreactivity
         </strong>
         – Finally, the autoimmune response can be kept in check by active regulation [
         <a href="#rid78">
          78
         </a>
         ]. Regulatory T cells (Tregs) are diverse in properties and origin; some arise in the thymus as an alternative fate of antigen-specific cells rather than deletion. This fate may depend on the strength of interaction of developing T cells with antigen-presenting cells in the thymus [
         <a href="#rid79">
          79,80
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Among the major regulatory cells are a subset of T cells bearing the markers CD4, CD25, and forkhead box protein P3 (FOXP3) [
         <a href="#rid81">
          81
         </a>
         ]. Two different subpopulations of CD4+ Tregs can be distinguished. Naturally recurring Tregs exert their suppressive effects by cell-to-cell contact of membrane-bound molecules, such as CTLA-4. Induced Tregs, in contrast, are cell-contact-independent and operate mainly through soluble suppressive cytokines, such as interleukin (IL) 10 and transforming growth factor (TGF)-beta [
         <a href="#rid82">
          82
         </a>
         ]. Treg function and phenotype can exhibit plasticity, and cells with diminished suppressive capacity may be seen in some autoimmune disorders [
         <a href="#rid83">
          83,84
         </a>
         ]. Studies in animals show that antigen-specific Tregs are more effective in suppressing autoimmune disease when compared with polyclonal Tregs [
         <a href="#rid85">
          85
         </a>
         ]. Clinical trials of antigen-specific Tregs are underway in organ-specific autoimmune diseases [
         <a href="#rid86">
          86
         </a>
         ]. Other specialized populations of T cells such as some that express the natural killer (NK) receptor (called NK-T cells) can also regulate autoimmune disease [
         <a href="#rid78">
          78,87
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A heritable defect in the suppressive effects of CD4+ CD25+ FOXP3 Tregs appears to be the mechanism underlying the rare lethal autoimmune human disease "immune dysregulation, polyendocrinopathy, enteropathy, X-linked" (IPEX syndrome, MIM 304790). Mutations in the FOXP3 located on the X chromosome have been noted in most of the affected patients [
         <a href="#rid88">
          88
         </a>
         ]. In a mouse model, deficiency of FOXP3 results in an absence of CD4+ CD25+ T cells. In humans with IPEX, the number of Tregs appears to be normal, but their ability to suppress autologous effector T cells is markedly impaired [
         <a href="#rid89">
          89
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3924.html" rel="external">
          "IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Defects in regulation of autoimmune B cell responses
         </strong>
         – Like the regulation of T cells, regulation of B cell responses occurs at multiple levels, both centrally and peripherally. As the B cell repertoire develops, autoreactive cells are eliminated at various steps, called checkpoints, by mechanisms that include deletion, anergy, and receptor editing. Receptor editing involves a secondary gene rearrangement to replace an autoreactive immunoglobulin receptor with one of another specificity. Since B cell responses involve the generation of somatic mutants to increase antibody affinity, regulatory interactions are key throughout an immune response since a somatic mutant generated to a foreign antigen could inadvertently bind a self-antigen. Studies on patients with systemic lupus erythematosus indicate disturbances in immune checkpoints, with an increased presence of autoreactive B cells in the preimmune repertoire [
         <a href="#rid90">
          90-92
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Targeting of cell surface and soluble antigens and immune complex formation
         </strong>
         – Whether clinical manifestations of autoimmune disease will follow from the presence of B or T cell autoreactivity depends upon both the quality of the immune response and the availability of the corresponding antigen. Antigens on the surface of circulating cells such as blood cells are readily available to circulating antibody and, therefore, such cells may be damaged or eliminated by autoantibody acting with complement, cytotoxic T cells, or phagocytes [
         <a href="#rid93">
          93
         </a>
         ]. The receptors on cell surfaces such as the thyroid-stimulating hormone (TSH) receptor on the thyroid cell or the acetylcholine receptor at neuromuscular junctions may also be directly bound by autoantibody [
         <a href="#rid94">
          94
         </a>
         ]. This interaction may result in stimulating the receptor in Graves' disease or in blocking the neuromuscular transmission as observed in myasthenia gravis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In other diseases, autoantibodies are produced to particular enzymes. As an example, antibodies to the P450 enzymes are prominent in autoimmune hepatitis and primary biliary cholangitis (previously referred to as primary biliary cirrhosis) [
         <a href="#rid95">
          95,96
         </a>
         ]. These enzymes are widely distributed in the body, raising the questions of why the diseases are organ-specific. Evidence suggests that the enzymes may be accessible to antibodies or T cells primarily in reactivated locations.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immune complexes
         </strong>
         – An important mechanism for autoimmune disease is the formation of immune complexes between autoantibodies and the corresponding autoantigen present in the circulation and/or on cell surfaces. For systemic lupus erythematosus, immune complexes of anti-DNA antibodies with DNA can deposit in the kidney and activate complement to produce nephritis [
         <a href="#rid97">
          97
         </a>
         ]. These immune complexes can also enter cells of the innate immune system to stimulate the production of cytokines, most prominently type 1 interferon, by interaction with internal nucleic acid sensors. Autoantibodies to ribonucleic acid (RNA)-binding proteins (RBPs) can also stimulate the production of cytokines since the RNA associated with RBPs can interact with these sensors. The formation of immune complexes depends on the amount of antibody, its properties (eg, avidity), and the availability of self-antigen [
         <a href="#rid98">
          98
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The ability of immune complexes to stimulate cytokine production demonstrates an important feature of nucleic acids as targets of autoantibodies. Unlike many autoantigens, DNA and RNA have intrinsic immunostimulatory activity, likely related to the role of internal nucleic acid sensors in host defense; these sensors can detect DNA and RNA in the cytoplasm of cells and, therefore, can respond to intracellular infection from bacteria or viruses [
         <a href="#rid99">
          99
         </a>
         ]. Deficiency of the nucleases that degrade DNA and RNA either intracellularly or extracellularly can also lead to autoimmunity in both patients and animal models. The production of anti-DNA antibodies is a notable consequence of deficiency of deoxyribonuclease (DNase) enzymes, with impaired degradation increasing the amount of self-DNA antigen available to stimulate autoantibody production [
         <a href="#rid100">
          100
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Effector T cell-mediated injury
         </strong>
         – While many other autoimmune diseases result from direct effects of autoantibodies, some diseases are associated with T cell-mediated immune responses. Sometimes, cytotoxic effector T cells may be generated that can damage their respective target cell [
         <a href="#rid101">
          101
         </a>
         ]. In other cases, cytokines are produced that are harmful to surrounding tissue cells [
         <a href="#rid102">
          102
         </a>
         ]. Finally, T cells may activate macrophages, which can produce a tissue injury through their soluble products, including cytokines and reactive oxygen intermediates. A functionally significant polymorphism of a lymphocyte specific phosphatase known as the protein tyrosine phosphatase non-receptor 22 gene (
         <em>
          PTPN22
         </em>
         ) has been linked to T cell hyperresponsiveness. Carriage of the 1858T variant of
         <em>
          PTPN22
         </em>
         is associated with several autoimmune conditions, including rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, and type 1 diabetes mellitus [
         <a href="#rid103">
          103
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Innate immune mechanisms
         </strong>
         – High-throughput genetic and genomic studies have also focused attention on innate mechanisms in autoimmunity [
         <a href="#rid104">
          104
         </a>
         ]. The innate immune system uses sets of molecules known as pattern-recognition receptors that have been selected through evolution to recognize molecular patterns found in microorganisms. Families of pattern-recognition receptors include the toll-like receptors, the nucleotide oligomerization domain-like receptors, and the NACHT leucine-rich-repeat proteins (NALPs) [
         <a href="#rid105">
          105,106
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13572.html" rel="external">
          "An overview of the innate immune system"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Both NALP1 and NALP3 comprise part of cytoplasmic complexes called inflammasomes that regulate the activation of caspase 1, which converts ILs into their active forms [
         <a href="#rid107">
          107
         </a>
         ]. Variants of NALP1 are associated with autoimmune disorders that cluster with vitiligo (eg, autoimmune thyroid disease, latent autoimmune diabetes mellitus in adults, rheumatoid arthritis, psoriasis, pernicious anemia, and Addison disease) [
         <a href="#rid108">
          108
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Roles of T cell subsets
         </strong>
         – In human disease, it is frequently impossible to clearly separate the injury that is from antibody-mediated in contrast to cell-mediated reactions. In general, however, the T cell-mediated responses are associated with the T helper (Th) 1 subset of CD4+ T cells [
         <a href="#rid109">
          109
         </a>
         ]. Antibody-mediated mechanisms, in general, associate with Th2 responses. Thus, some autoimmune disorders may benefit by a shift from a Th1 to a Th2 response, which can be mediated therapeutically.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This original simplistic view of the Th1/Th2 dichotomy is not easily applied to human disease in which both Th1 and Th2 responses are generally evident. In fact, some autoimmune diseases are actually downregulated by administering interferon-gamma, the prototypic Th1 cytokine [
         <a href="#rid110">
          110
         </a>
         ]. It is now evident that a third T cell subset producing IL-17 (termed Th17) plays a critical role in several autoimmune conditions. Interestingly, there is a reciprocal relationship between Th17 and Tregs that may dictate the final outcome of an autoimmune reaction. Inflammatory cytokines TGF-gamma and interferon-gamma play central roles in setting the balance [
         <a href="#rid111">
          111
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H189998077">
         <span class="h1">
          AUTOINFLAMMATORY DISEASES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The term "autoinflammatory disease" refers to a group of mostly inherited disorders that resemble in some respects the traditional autoimmune diseases in terms of the presence of inflammation as well as multisystem manifestations [
         <a href="#rid112">
          112
         </a>
         ]. These disorders are distinguished by the absence of a defined adaptive immune response. The prototypic disorders were in a group of "hereditary periodic fever syndromes" that commonly share involvement of certain specific cytokines such as interleukin (IL) 1-beta and tumor necrosis factor (TNF). Study of these disorders have revealed a prominent role for the innate immune system. The category of autoinflammatory diseases has gradually expanded to include a group of disorders sharing an abnormally increased inflammatory response mediated predominantly by cells and molecules of the innate immune system with a significant host predisposition. (See
         <a class="medical medical_review" href="/z/d/html/5597.html" rel="external">
          "The autoinflammatory diseases: An overview"
         </a>
         .)
        </p>
        <p>
         Mutant NACHT leucine-rich-repeat protein 3 (NALP3), also known as cryopyrin, is linked to three inflammatory disorders associated with autosomal dominant inheritance: familial cold urticaria syndrome, Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease (see
         <a class="medical medical_review" href="/z/d/html/5585.html" rel="external">
          "Cryopyrin-associated periodic syndromes and related disorders"
         </a>
         ). A related group of diseases is characterized by increased levels of interferon. These diseases are termed interferonopathies and result from mutations in a variety of genes [
         <a href="#rid113">
          113
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/116307.html" rel="external">
          "Autoinflammatory diseases mediated by interferon production and signaling (interferonopathies)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1450730">
         <span class="h1">
          VACCINES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The protective value of vaccines in patients with autoimmune disease is well established based on sound epidemiologic data, while the possibility that vaccines may induce or exacerbate autoimmune disease remains speculative [
         <a href="#rid114">
          114,115
         </a>
         ].
        </p>
        <p>
         While immunization is a powerful approach to reduce the occurrence of infectious diseases, concerns about safety have been raised especially in the lay press. An important component of certain vaccines is a substance known as an adjuvant of which alum is commonly used. An adjuvant can trigger the innate immune system to promote the immune response to the vaccinating antigen, raising the possibility that a response to a self-antigen can also be induced. In general, patients with an autoimmune disease have increased immune reactivity, but there are no well-designed epidemiologic studies showing a significant increase in any autoimmune disease following vaccination of these patients including coronavirus disease 2019 (COVID-19) RNA vaccination [
         <a href="#rid116">
          116
         </a>
         ].
        </p>
        <p>
         Other studies fail to show severe systemic adverse effects, including autoimmune disorders, with immunization using adjuvant compared with nonadjuvanted vaccines. Indeed, many patients with autoimmune disease are relatively poor immune responders to vaccine antigens and may require additional boosters. (See
         <a class="medical medical_review" href="/z/d/html/103773.html" rel="external">
          "Immunizations in autoimmune inflammatory rheumatic disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3519079">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Autoimmune disease is a pathologic condition caused by an adaptive autoimmune response directed against an antigen within the body of the host, termed a self-antigen. The response may be induced by a foreign or self-antigen. It usually involves both a T and B cell response. (See
         <a class="local">
          'Definition'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Features of autoimmune disease
         </strong>
         – The demonstration of autoantibodies is usually the first step in the diagnosis of an autoimmune disease, although it is not sufficient. The antibodies may not be the actual mediators of disease. Naturally occurring autoantibodies can occur in immunologically competent people and may even rise nonspecifically during the course of disease or injury. (See
         <a class="local">
          'Features of autoimmune disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evidence of causality
         </strong>
         – There are various levels of evidence in studies of the causality of autoimmune disease. Direct evidence requires demonstration that autoimmune response can produce the disease. Indirect evidence typically involves manipulation of the immune system or study of naturally occurring disease in animal models. Finally, circumstantial evidence is most common and includes studies on the presence of autoantibodies, clustering of diseases within an individual or family, bias to certain human leukocyte antigen (HLA) haplotypes, a sex bias, and a response to immunosuppressive therapy. (See
         <a class="local">
          'Direct evidence'
         </a>
         above and
         <a class="local">
          'Indirect evidence'
         </a>
         above and
         <a class="local">
          'Circumstantial evidence'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inductive mechanisms
         </strong>
         – An autoimmune response can be initiated by autologous or foreign antigens. Like all immune responses, autoimmunity appears under strict genetic control of antigen recognition, cellular interactions, and eventual outcomes. (See
         <a class="local">
          'Inductive mechanisms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenic mechanisms
         </strong>
         – The development of autoimmune disease depends upon an imbalance between pathogenic factors generated by autoreactive T and B cells and the regulatory factors that normally control the immune response. For example, the balance of activities between various effector T cells and regulatory T cells (Tregs) helps to determine whether an individual maintains normal self-tolerance or progresses to autoimmune disease. (See
         <a class="local">
          'Pathogenetic mechanisms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Autoinflammatory diseases
         </strong>
         – Diseases in which there is chronic inflammation but no evidence of autoreactive T or B cells, termed autoinflammatory diseases, are associated with the innate immune response. (See
         <a class="local">
          'Autoinflammatory diseases'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vaccines
         </strong>
         – The protective value of vaccines in patients with autoimmune disease is well established based on sound epidemiologic data, while the possibility that vaccines may induce or exacerbate autoimmune disease remains speculative. In general, patients with an autoimmune disease have increased immune reactivity, but there are no well-designed epidemiologic studies showing a significant increase in any autoimmune disease following vaccination of these patients. (See
         <a class="local">
          'Vaccines'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3239032279">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Noel R Rose, MD, PhD, now deceased, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Rose NR. Autoimmune diseases: tracing the shared threads. Hosp Pract (1995) 1997; 32:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001; 345:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strle K, Sulka KB, Pianta A, et al. T-Helper 17 Cell Cytokine Responses in Lyme Disease Correlate With Borrelia burgdorferi Antibodies During Early Infection and With Autoantibodies Late in the Illness in Patients With Antibiotic-Refractory Lyme Arthritis. Clin Infect Dis 2017; 64:930.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rose NR. Viral myocarditis. Curr Opin Rheumatol 2016; 28:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol 2018; 18:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pisetsky DS, Lipsky PE. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nat Rev Rheumatol 2020; 16:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schur PH. Laboratory testing for the diagnosis, evaluation, and management of systemic lupus erythematosus: Still more questions for the next generations: A Tribute and Thanks and in Memory of my mentor: Henry G. Kunkel. Clin Immunol 2016; 172:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dinse GE, Parks CG, Weinberg CR, et al. Increasing Prevalence of Antinuclear Antibodies in the United States. Arthritis Rheumatol 2020; 72:1026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenfeld MR, Dalmau J. Paraneoplastic Neurologic Syndromes. Neurol Clin 2018; 36:675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen JJ, Pittock SJ, Flanagan EP, et al. Optic neuritis in the era of biomarkers. Surv Ophthalmol 2020; 65:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lu R, Munroe ME, Guthridge JM, et al. Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies. J Autoimmun 2016; 74:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slight-Webb S, Lu R, Ritterhouse LL, et al. Autoantibody-Positive Healthy Individuals Display Unique Immune Profiles That May Regulate Autoimmunity. Arthritis Rheumatol 2016; 68:2492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349:1526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rose NR. Predictors of autoimmune disease: autoantibodies and beyond. Autoimmunity 2008; 41:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gutierrez-Arcelus M, Rich SS, Raychaudhuri S. Autoimmune diseases - connecting risk alleles with molecular traits of the immune system. Nat Rev Genet 2016; 17:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today 1993; 14:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pisetsky DS. Fulfilling Koch's postulates of autoimmunity: anti-NR2 antibodies in mice and men. Arthritis Rheum 2006; 54:2349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anhalt GJ, Labib RS, Voorhees JJ, et al. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982; 306:1189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burman KD, Baker JR Jr. Immune mechanisms in Graves' disease. Endocr Rev 1985; 6:183.
          </a>
         </li>
         <li class="breakAll">
          Drachman DB. How to recognize an antibody-mediated autoimmune disease: Criteria. In: Immunologic Mechanisms in Neurologic and Psychiatric Disease, Waksman BH (Ed), Raven, New York 1990. p.183.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reichlin M, Brucato A, Frank MB, et al. Concentration of autoantibodies to native 60-kd Ro/SS-A and denatured 52-kd Ro/SS-A in eluates from the heart of a child who died with congenital complete heart block. Arthritis Rheum 1994; 37:1698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hornberger LK, Al Rajaa N. Spectrum of cardiac involvement in neonatal lupus. Scand J Immunol 2010; 72:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clancy RM, Kapur RP, Molad Y, et al. Immunohistologic evidence supports apoptosis, IgG deposition, and novel macrophage/fibroblast crosstalk in the pathologic cascade leading to congenital heart block. Arthritis Rheum 2004; 50:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           HARTMANN RC, CONLEY CL. Studies on the initiation of blood coagulation, III. The clotting properties of canine platelet-free plasma. J Clin Invest 1952; 31:685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vali M, Rose NR, Caturegli P. Thyroglobulin as autoantigen: structure-function relationships. Rev Endocr Metab Disord 2000; 1:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rose NR, Hill SL. The pathogenesis of postinfectious myocarditis. Clin Immunol Immunopathol 1996; 80:S92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swanborg RH. Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease. Clin Immunol Immunopathol 1995; 77:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baxter AG. The origin and application of experimental autoimmune encephalomyelitis. Nat Rev Immunol 2007; 7:904.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weissert R, Kuhle J, de Graaf KL, et al. High immunogenicity of intracellular myelin oligodendrocyte glycoprotein epitopes. J Immunol 2002; 169:548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waldner H, Collins M, Kuchroo VK. Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease. J Clin Invest 2004; 113:990.
          </a>
         </li>
         <li class="breakAll">
          Theofilopoulos AN. Immunologic genes in mouse lupus models. In: The Molecular Pathology of Autoimmune Diseases, Bona CA, Siminovich KA, Zanetti M, Theofilopoulos AN (Eds), Harwood, Chur, Switzerland 1993. p.281.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobel ES, Katagiri T, Katagiri K, et al. An intrinsic B cell defect is required for the production of autoantibodies in the lpr model of murine systemic autoimmunity. J Exp Med 1991; 173:1441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu J, Liu X, Xie C, et al. T cell hyperactivity in lupus as a consequence of hyperstimulatory antigen-presenting cells. J Clin Invest 2005; 115:1869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang Y, Liu Q, Yu Y, et al. Early and Short-Term Interventions in the Gut Microbiota Affects Lupus Severity, Progression, and Treatment in MRL/lpr Mice. Front Microbiol 2020; 11:628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leiter EH, Prochazka M, Coleman DL. The non-obese diabetic (NOD) mouse. Am J Pathol 1987; 128:380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huber A, Menconi F, Corathers S, et al. Joint genetic susceptibility to type 1 diabetes and autoimmune thyroiditis: from epidemiology to mechanisms. Endocr Rev 2008; 29:697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohan C. The Long (and Sometimes Endless) Road to Murine Lupus Genes. J Immunol 2015; 195:4043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richard ML, Gilkeson G. Mouse models of lupus: what they tell us and what they don't. Lupus Sci Med 2018; 5:e000199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mangalam AK, Rajagopalan G, Taneja V, David CS. HLA class II transgenic mice mimic human inflammatory diseases. Adv Immunol 2008; 97:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elliott JF, Liu J, Yuan ZN, et al. Autoimmune cardiomyopathy and heart block develop spontaneously in HLA-DQ8 transgenic IAbeta knockout NOD mice. Proc Natl Acad Sci U S A 2003; 100:13447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horak I, Löhler J, Ma A, Smith KA. Interleukin-2 deficient mice: a new model to study autoimmunity and self-tolerance. Immunol Rev 1995; 148:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kühn R, Löhler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okazaki T, Tanaka Y, Nishio R, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 2003; 9:1477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med 2018; 378:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinmann SC, Pisetsky DS. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. Rheumatology (Oxford) 2019; 58:vii59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avrameas S, Alexopoulos H, Moutsopoulos HM. Natural Autoantibodies: An Undersugn Hero of the Immune System and Autoimmune Disorders-A Point of View. Front Immunol 2018; 9:1320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frustaci A, Cuoco L, Chimenti C, et al. Celiac disease associated with autoimmune myocarditis. Circulation 2002; 105:2611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eaton WW, Rose NR, Kalaydjian A, et al. Epidemiology of autoimmune diseases in Denmark. J Autoimmun 2007; 29:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rose NR. The genetics of autoimmune thyroiditis: the first decade. J Autoimmun 2011; 37:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Effraimidis G, Wiersinga WM. Mechanisms in endocrinology: autoimmune thyroid disease: old and new players. Eur J Endocrinol 2014; 170:R241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stanford SM, Bottini N. PTPN22: the archetypal non-HLA autoimmunity gene. Nat Rev Rheumatol 2014; 10:602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bogdanos DP, Smyk DS, Rigopoulou EI, et al. Twin studies in autoimmune disease: genetics, gender and environment. J Autoimmun 2012; 38:J156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hensvold AH, Magnusson PK, Joshua V, et al. Environmental and genetic factors in the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: an epidemiological investigation in twins. Ann Rheum Dis 2015; 74:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta B, Hawkins RD. Epigenomics of autoimmune diseases. Immunol Cell Biol 2015; 93:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a pathological perspective. Am J Pathol 2008; 173:600.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubtsova K, Marrack P, Rubtsov AV. Sexual dimorphism in autoimmunity. J Clin Invest 2015; 125:2187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol 2016; 16:626.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris VM, Koelsch KA, Kurien BT, et al. Characterization of cxorf21 Provides Molecular Insight Into Female-Bias Immune Response in SLE Pathogenesis. Front Immunol 2019; 10:2160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pianta A, Arvikar SL, Strle K, et al. Two rheumatoid arthritis-specific autoantigens correlate microbial immunity with autoimmune responses in joints. J Clin Invest 2017; 127:2946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller FW, Pollard KM, Parks CG, et al. Criteria for environmentally associated autoimmune diseases. J Autoimmun 2012; 39:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mackay IR, Leskovsek NV, Rose NR. Cell damage and autoimmunity: a critical appraisal. J Autoimmun 2008; 30:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rose NR. Negative selection, epitope mimicry and autoimmunity. Curr Opin Immunol 2017; 49:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elson CO, Alexander KL. Host-microbiota interactions in the intestine. Dig Dis 2015; 33:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scher JU, Sczesnak A, Longman RS, et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife 2013; 2:e01202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azzouz D, Omarbekova A, Heguy A, et al. Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal. Ann Rheum Dis 2019; 78:947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azzouz DF, Chen Z, Izmirly PM, et al. Longitudinal gut microbiome analyses and blooms of pathogenic strains during lupus disease flares. Ann Rheum Dis 2023; 82:1315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manfredo Vieira S, Hiltensperger M, Kumar V, et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science 2018; 359:1156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fairweather D, Frisancho-Kiss S, Rose NR. Viruses as adjuvants for autoimmunity: evidence from Coxsackievirus-induced myocarditis. Rev Med Virol 2005; 15:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           James JA, Harley JB, Scofield RH. Epstein-Barr virus and systemic lupus erythematosus. Curr Opin Rheumatol 2006; 18:462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ascherio A, Munger KL. EBV and Autoimmunity. Curr Top Microbiol Immunol 2015; 390:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grateau G, Duruöz MT. Autoinflammatory conditions: when to suspect? How to treat? Best Pract Res Clin Rheumatol 2010; 24:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nemazee D. Mechanisms of central tolerance for B cells. Nat Rev Immunol 2017; 17:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein L, Robey EA, Hsieh CS. Central CD4+ T cell tolerance: deletion versus regulatory T cell differentiation. Nat Rev Immunol 2019; 19:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yi J, Kawabe T, Sprent J. New insights on T-cell self-tolerance. Curr Opin Immunol 2020; 63:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Martino L, Capalbo D, Improda N, et al. APECED: A Paradigm of Complex Interactions between Genetic Background and Susceptibility Factors. Front Immunol 2013; 4:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dighiero G, Rose NR. Critical self-epitopes are key to the understanding of self-tolerance and autoimmunity. Immunol Today 1999; 20:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamradt T, Mitchison NA. Tolerance and autoimmunity. N Engl J Med 2001; 344:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King C, Ilic A, Koelsch K, Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004; 117:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10:490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plitas G, Rudensky AY. Regulatory T Cells: Differentiation and Function. Cancer Immunol Res 2016; 4:721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buckner JH, Ziegler SF. Functional analysis of FOXP3. Ann N Y Acad Sci 2008; 1143:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jonuleit H, Schmitt E. The regulatory T cell family: distinct subsets and their interrelations. J Immunol 2003; 171:6323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou X, Bailey-Bucktrout SL, Jeker LT, et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 2009; 10:1000.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dominguez-Villar M, Baecher-Allan CM, Hafler DA. Identification of T helper type 1-like, Foxp3+ regulatory T cells in human autoimmune disease. Nat Med 2011; 17:673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spence A, Klementowicz JE, Bluestone JA, Tang Q. Targeting Treg signaling for the treatment of autoimmune diseases. Curr Opin Immunol 2015; 37:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharabi A, Tsokos MG, Ding Y, et al. Regulatory T cells in the treatment of disease. Nat Rev Drug Discov 2018; 17:823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McHugh RS, Shevach EM. Cutting edge: depletion of CD4+CD25+ regulatory T cells is necessary, but not sufficient, for induction of organ-specific autoimmune disease. J Immunol 2002; 168:5979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wildin RS, Smyk-Pearson S, Filipovich AH. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet 2002; 39:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bacchetta R, Passerini L, Gambineri E, et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest 2006; 116:1713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yurasov S, Wardemann H, Hammersen J, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 2005; 201:703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meffre E, O'Connor KC. Impaired B-cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies. Immunol Rev 2019; 292:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suurmond J, Atisha-Fregoso Y, Marasco E, et al. Loss of an IgG plasma cell checkpoint in patients with lupus. J Allergy Clin Immunol 2019; 143:1586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berentsen S, Sundic T. Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy. Biomed Res Int 2015; 2015:363278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazaridis K, Tzartos SJ. Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics. Front Immunol 2020; 11:212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bogdanos DP, Dalekos GN. Enzymes as target antigens of liver-specific autoimmunity: the case of cytochromes P450s. Curr Med Chem 2008; 15:2285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lleo A, Invernizzi P, Mackay IR, et al. Etiopathogenesis of primary biliary cirrhosis. World J Gastroenterol 2008; 14:3328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang X, Xia Y. Anti-double Stranded DNA Antibodies: Origin, Pathogenicity, and Targeted Therapies. Front Immunol 2019; 10:1667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pisetsky DS. The central role of nucleic acids in the pathogenesis of systemic lupus erythematosus. F1000Res 2019; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Unterholzner L, Almine JF. Camouflage and interception: how pathogens evade detection by intracellular nucleic acid sensors. Immunology 2019; 156:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soni C, Reizis B. Self-DNA at the Epicenter of SLE: Immunogenic Forms, Regulation, and Effects. Front Immunol 2019; 10:1601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blanco P, Viallard JF, Pellegrin JL, Moreau JF. Cytotoxic T lymphocytes and autoimmunity. Curr Opin Rheumatol 2005; 17:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ueda H, Howson JM, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423:506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee YH, Rho YH, Choi SJ, et al. The PTPN22 C1858T functional polymorphism and autoimmune diseases--a meta-analysis. Rheumatology (Oxford) 2007; 46:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gregersen PK. Modern genetics, ancient defenses, and potential therapies. N Engl J Med 2007; 356:1263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature 2006; 442:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawai T, Akira S. Toll-like receptor and RIG-I-like receptor signaling. Ann N Y Acad Sci 2008; 1143:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinon F, Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 2007; 14:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jin Y, Mailloux CM, Gowan K, et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 2007; 356:1216.
          </a>
         </li>
         <li class="breakAll">
          Emmi L, Romagnani S. Role of Th1 and Th2 cells in autoimmunity. In: The Autoimmune Diseases, Rose NR, Mackay IR (Eds), Academic Press, San Diego 2006. p.83.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Afanasyeva M, Georgakopoulos D, Rose NR. Autoimmune myocarditis: cellular mediators of cardiac dysfunction. Autoimmun Rev 2004; 3:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez GJ, Nurieva RI, Yang XO, Dong C. Regulation and function of proinflammatory TH17 cells. Ann N Y Acad Sci 2008; 1143:188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park H, Bourla AB, Kastner DL, et al. Lighting the fires within: the cell biology of autoinflammatory diseases. Nat Rev Immunol 2012; 12:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanchez GAM, Reinhardt A, Ramsey S, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest 2018; 128:3041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oppermann M, Fritzsche J, Weber-Schoendorfer C, et al. A(H1N1)v2009: a controlled observational prospective cohort study on vaccine safety in pregnancy. Vaccine 2012; 30:4445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murdaca G, Orsi A, Spano F, et al. Influenza and pneumococcal vaccination of patients with systemic lupus erythematosus: current views upon safety and immunogenicity. Autoimmun Rev 2013; :in press.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Świerkot J, Madej M, Szmyrka M, et al. The Risk of Autoimmunity Development following mRNA COVID-19 Vaccination. Viruses 2022; 14.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5579 Version 28.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9109812" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Autoimmune diseases: tracing the shared threads.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11484692" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Autoimmune diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28077518" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : T-Helper 17 Cell Cytokine Responses in Lyme Disease Correlate With Borrelia burgdorferi Antibodies During Early Infection and With Autoantibodies Late in the Illness in Patients With Antibiotic-Refractory Lyme Arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27166925" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Viral myocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28990587" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Neutrophil extracellular traps in immunity and disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32884126" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : New insights into the role of antinuclear antibodies in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27506962" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Laboratory testing for the diagnosis, evaluation, and management of systemic lupus erythematosus: Still more questions for the next generations: A Tribute and Thanks and in Memory of my mentor: Henry G. Kunkel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32266792" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Increasing Prevalence of Antinuclear Antibodies in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30072076" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Paraneoplastic Neurologic Syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31425702" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Optic neuritis in the era of biomarkers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27338520" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27059145" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Autoantibody-Positive Healthy Individuals Display Unique Immune Profiles That May Regulate Autoimmunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14561795" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Development of autoantibodies before the clinical onset of systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18781467" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Predictors of autoimmune disease: autoantibodies and beyond.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26907721" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Autoimmune diseases - connecting risk alleles with molecular traits of the immune system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8216719" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Defining criteria for autoimmune diseases (Witebsky's postulates revisited)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16868989" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Fulfilling Koch's postulates of autoimmunity: anti-NR2 antibodies in mice and men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7040962" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2988930" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Immune mechanisms in Graves' disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2988930" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Immune mechanisms in Graves' disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7980679" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Concentration of autoantibodies to native 60-kd Ro/SS-A and denatured 52-kd Ro/SS-A in eluates from the heart of a child who died with congenital complete heart block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20696015" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Spectrum of cardiac involvement in neonatal lupus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14730614" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Immunohistologic evidence supports apoptosis, IgG deposition, and novel macrophage/fibroblast crosstalk in the pathologic cascade leading to congenital heart block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14938443" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Studies on the initiation of blood coagulation, III. The clotting properties of canine platelet-free plasma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11704994" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Thyroglobulin as autoantigen: structure-function relationships.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8811068" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The pathogenesis of postinfectious myocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7554482" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17917672" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The origin and application of experimental autoimmune encephalomyelitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12077287" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : High immunogenicity of intracellular myelin oligodendrocyte glycoprotein epitopes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15057305" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15057305" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2033370" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : An intrinsic B cell defect is required for the production of autoantibodies in the lpr model of murine systemic autoimmunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15951839" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : T cell hyperactivity in lupus as a consequence of hyperstimulatory antigen-presenting cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32346376" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Early and Short-Term Interventions in the Gut Microbiota Affects Lupus Severity, Progression, and Treatment in MRL/lpr Mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3303953" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The non-obese diabetic (NOD) mouse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18776148" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Joint genetic susceptibility to type 1 diabetes and autoimmune thyroiditis: from epidemiology to mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26477046" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The Long (and Sometimes Endless) Road to Murine Lupus Genes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29387435" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Mouse models of lupus: what they tell us and what they don't.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18501769" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : HLA class II transgenic mice mimic human inflammatory diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14570980" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Autoimmune cardiomyopathy and heart block develop spontaneously in HLA-DQ8 transgenic IAbeta knockout NOD mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8825281" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Interleukin-2 deficient mice: a new model to study autoimmunity and self-tolerance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8402911" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Interleukin-10-deficient mice develop chronic enterocolitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14595408" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29320654" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31816080" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29946320" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Natural Autoantibodies: An Undersugn Hero of the Immune System and Autoimmune Disorders-A Point of View.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12045166" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Celiac disease associated with autoimmune myocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17582741" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Epidemiology of autoimmune diseases in Denmark.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21683550" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : The genetics of autoimmune thyroiditis: the first decade.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24609834" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Mechanisms in endocrinology: autoimmune thyroid disease: old and new players.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25003765" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : PTPN22: the archetypal non-HLA autoimmunity gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22177232" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Twin studies in autoimmune disease: genetics, gender and environment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24276366" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Environmental and genetic factors in the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: an epidemiological investigation in twins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25776989" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Epigenomics of autoimmune diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18688037" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Sex differences in autoimmune disease from a pathological perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25915581" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Sexual dimorphism in autoimmunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27546235" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Sex differences in immune responses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31695690" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Characterization of cxorf21 Provides Molecular Insight Into Female-Bias Immune Response in SLE Pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28650341" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Two rheumatoid arthritis-specific autoantigens correlate microbial immunity with autoimmune responses in joints.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22771005" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Criteria for environmentally associated autoimmune diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18194728" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Cell damage and autoimmunity: a critical appraisal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29102863" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Negative selection, epitope mimicry and autoimmunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25925913" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Host-microbiota interactions in the intestine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24192039" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30782585" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37365013" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Longitudinal gut microbiome analyses and blooms of pathogenic strains during lupus disease flares.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29590047" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Translocation of a gut pathobiont drives autoimmunity in mice and humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15386590" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Viruses as adjuvants for autoimmunity: evidence from Coxsackievirus-induced myocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16896283" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Epstein-Barr virus and systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26424654" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : EBV and Autoimmunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20534373" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Autoinflammatory conditions: when to suspect? How to treat?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28368006" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Mechanisms of central tolerance for B cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30420705" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Central CD4+ T cell tolerance: deletion versus regulatory T cell differentiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31786417" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : New insights on T-cell self-tolerance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24167503" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : APECED: A Paradigm of Complex Interactions between Genetic Background and Susceptibility Factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10462743" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Critical self-epitopes are key to the understanding of self-tolerance and autoimmunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11228281" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Tolerance and autoimmunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15084263" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Homeostatic expansion of T cells during immune insufficiency generates autoimmunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20559327" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : FOXP3+ regulatory T cells in the human immune system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27590281" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Regulatory T Cells: Differentiation and Function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19076349" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Functional analysis of FOXP3.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14662827" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : The regulatory T cell family: distinct subsets and their interrelations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19633673" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21540856" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Identification of T helper type 1-like, Foxp3+ regulatory T cells in human autoimmune disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26432763" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Targeting Treg signaling for the treatment of autoimmune diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30310234" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Regulatory T cells in the treatment of disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12055202" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Cutting edge: depletion of CD4+CD25+ regulatory T cells is necessary, but not sufficient, for induction of organ-specific autoimmune disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12161590" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16741580" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Defective regulatory and effector T cell functions in patients with FOXP3 mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15738055" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Defective B cell tolerance checkpoints in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31721234" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Impaired B-cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30439406" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Loss of an IgG plasma cell checkpoint in patients with lupus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25705656" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32117321" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18781950" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Enzymes as target antigens of liver-specific autoimmunity: the case of cytochromes P450s.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18528930" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Etiopathogenesis of primary biliary cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31379858" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Anti-double Stranded DNA Antibodies: Origin, Pathogenicity, and Targeted Therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31001416" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : The central role of nucleic acids in the pathogenesis of systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30499584" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Camouflage and interception: how pathogens evade detection by intracellular nucleic acid sensors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31354738" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Self-DNA at the Epicenter of SLE: Immunogenic Forms, Regulation, and Effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16224251" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Cytotoxic T lymphocytes and autoimmunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12724780" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16760194" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : The PTPN22 C1858T functional polymorphism and autoimmune diseases--a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17377166" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Modern genetics, ancient defenses, and potential therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16823444" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Intracellular pattern recognition receptors in the host response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19076341" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Toll-like receptor and RIG-I-like receptor signaling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16977329" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Inflammatory caspases and inflammasomes: master switches of inflammation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17377159" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : NALP1 in vitiligo-associated multiple autoimmune disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17377159" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : NALP1 in vitiligo-associated multiple autoimmune disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15546794" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Autoimmune myocarditis: cellular mediators of cardiac dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19076351" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Regulation and function of proinflammatory TH17 cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22828911" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Lighting the fires within: the cell biology of autoinflammatory diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29649002" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22564554" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : A(H1N1)v2009: a controlled observational prospective cohort study on vaccine safety in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Influenza and pneumococcal vaccination of patients with systemic lupus erythematosus: current views upon safety and immunogenicity
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36560659" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : The Risk of Autoimmunity Development following mRNA COVID-19 Vaccination.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
